Mipragoside
Mipragoside is a ganglioside derivative. Mipragoside can be studied in research on ocular inflammatory diseases such as keratoconjunctivitis[1].
Product Specifications
CAS Number
131129-98-1
UNSPSC
12352005
Target
Drug Derivative
Related Pathways
Others
Applications
COVID-19-immunoregulation
Field of Research
Infection
Smiles
CC(C)OC([C@@]1(O[C@@]([C@H](NC(C)=O)[C@@H](O)C1)([H])[C@H](O)[C@H](O)CO)O[C@H]2[C@H]([C@H](O[C@@H](O[C@]3([H])[C@H](O[C@@H](OC[C@H](NC(CCCCCCCCCCCCCCCCC)=O)[C@H](O)/C=C/CCCCCCCCCCCCC)[C@H](O)[C@H]3O)CO)[C@@H]2O)CO)O[C@@]4([H])[C@@H]([C@H]([C@@H](O)[C@@H](CO)O4)O[C@]5([H])O[C@@H]([C@H](O)[C@H](O)[C@H]5O)CO)NC(C)=O)=O
Molecular Formula
C76H137N3O31
Molecular Weight
1588.90
References & Citations
[1]Centofanti, M., et al., (1996) . Efficacy of mipragoside ophthalmic gel in vernal keratoconjunctivitis. Eye (London, England), 10 (Pt 4), 422-424.
Shipping Conditions
Room temperature
Scientific Category
Reference compound1
Clinical Information
No Development Reported
Frequently Asked Questions
More Discoveries
Explore Other Products
Browse additional items from our catalog
042229-ML405 100 µL
SPI1, CT (SPI1, Transcription factor PU.1, 31kD-transforming protein) (MaxLight 405) discontinued
Sign In for Pricing
View Details